This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
E. Germovsek, C. I. S. Barker, M. Sharland and J. F. Standing, Pharmacokinetic-pharmacodynamic modeling in pediatric drug development, and the importance of standardized scaling of clearance, Clin. Pharmacokinet.58(1) (2019) 39–52; https://doi.org/10.1007/s40262-018-0659-0Search in Google Scholar
H. Kimko and J. Pinheiro, Model-based clinical drug development in the past, present and future: a commentary, Br. J. Clin. Pharmacol.79(1) (2015) 108–116; https://doi.org/10.1111/bcp.12341Search in Google Scholar
K. J. Downes, A. Hahn, J. Wiles, J. D. Courter and A. A. Vinks, Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics, Int. J. Antimicrob. agents43(3) (2014) 223–230; https://doi.org/10.1016/j.ijantimicag.2013.11.006Search in Google Scholar
R. F. W. De Cock, C. Piana, E. H. J. Krekels, M. Danhof, K. Allegaert and C. A. J. Knibbe, The role of population PK-PD modelling in paediatric clinical research, Eur. J. Clin. Pharmacol.67 (2011) 5–16; https://doi.org/10.1007/s00228-009-0782-9Search in Google Scholar
UpToDate: Gentamicin (systemic): Pediatric drug information, 2022; last access date February 20, 2023.Search in Google Scholar
M. H. Abdul-Aziz, J.-W. C. Alffenaar, M. Bassetti, H. Bracht, G. Dimopoulos, D. Marriott, M. N. Neely, J.-A. Paiva, F. Pea and F. Sjovall, Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#, Intensive Care Med.46 (2020) 1127–1153; https://doi.org/10.1007/s00134-020-06050-1Search in Google Scholar
C. J. Hodiamont, A. K. van den Broek, S. L. de Vroom, J. M. Prins, R. A. Mathôt and R. M. van Hest, Clinical pharmacokinetics of gentamicin in various patient populations and consequences for optimal dosing for gram-negative infections: an updated review, Clin. Pharmacokinet.61 (2022) 1075–1094; https://doi.org/10.1007/s40262-022-01143-0Search in Google Scholar
P. Póvoa, P. Moniz, J. G. Pereira and L. Coelho, Optimizing antimicrobial drug dosing in critically ill patients, Microorganisms9(7) (2021) Article ID 1401 (27 pages); https://doi.org/10.3390/micro-organisms9071401Search in Google Scholar
J. M. Lanao, M. V. Calvo, J. A. Mesa, A. Martín-Suárez, M. T. Carbajosa, F. Miguelez and A. Domínguez-Gil, Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates, J. Antimicrob. Chemother.54(1) (2004) 193–198; https://doi.org/10.1093/jac/dkh261Search in Google Scholar
A. M. Jenh, P. D. Tamma and A. M. Milstone, Extended-interval aminoglycoside dosing in pediatrics, The Pediatr. Infect. Dis. J.30(4) (2011) 338–339; https://doi.org/10.1097/INF.0b013e31820f0f3aSearch in Google Scholar
S. J. McWilliam, D. J. Antoine, R. L. Smyth and M. Pirmohamed, Aminoglycoside-induced nephrotoxicity in children, Pediatr. Nephrol.32 (2017) 2015–2025; https://doi.org/10.1007/s00467-016-3533-zSearch in Google Scholar
F. A. Diepstraten, A. E. Hoetink, M. van Grotel, A. D. R. Huitema, R. J. Stokroos, M. M. van den Heuvel-Eibrik and A. J. M. Meijer, Aminoglycoside-and glycopeptide-induced ototoxicity in children: a systematic review, JAC-Antimicrob. Resist.3, dlab184 (2021), https://doi.org/10.1093/jacamr/dlab184Search in Google Scholar
A. Smits, P. Annaert and K. Allegaert, Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology, Int. J. Pharm.452(1–2) (2013) 8–13; https://doi.org/10.1016/j.ijpharm.2012.03.035Search in Google Scholar
H. Lu and S. Rosenbaum, Developmental pharmacokinetics in pediatric populations, J. Pediatr. Pharmacol. Ther.19(4) (2014) 262–276; https://doi.org/10.5863/1551-6776-19.4.262Search in Google Scholar
Y. A. Bijleveld, M. E. van den Heuvel, C. J. Hodiamont, R. A. Mathôt and T. R. de Haan, Population pharmacokinetics and dosing considerations for gentamicin in newborns with suspected or proven sepsis caused by Gram-negative bacteria, Antimicrob. Agents Chemother.61(1) (2017) e01304-16; https://doi.org/10.1128/AAC.01304-16Search in Google Scholar
S. J. F. Hartman, R. J. Brüggemann, L. Orriëns, N. Dia, M. F. Schreuder, S. N. De Wildt, Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature, Clin. Pharmacokinet.59 (2020) 173–205; https://doi.org/10.1007/s40262-019-00813-wSearch in Google Scholar
N. Thakkar, S. Salerno, C. P. Hornik and D. Gonzalez, Clinical pharmacology studies in critically ill children, Pharm. Res.34 (2017) 7–24; https://doi.org/10.1007/s11095-016-2033-ySearch in Google Scholar
D. J. Touw, E. M. Westerman and A. J. Sprij, Therapeutic drug monitoring of aminoglycosides in neonates, Clin. Pharmacokinet.48 (2019) 71–88; https://doi.org/10.2165/0003088-200948020-00001Search in Google Scholar
M. Crcek, J. Zdovc and M. Kerec Kos, A review of population pharmacokinetic models of gentamicin in paediatric patients, J. Clin. Pharm. Ther.44 (55) (2019) 659–674; https://doi.org/10.1111/jcpt.12850Search in Google Scholar
L. Martin, N. Jimenez and A. M. Lynn, Developmental pharmacokinetics and pharmacodynamics of parenteral opioids and nonsteroidal anti-inflammatory drugs in neonates and infants, Colomb. J. Anestesiol.45 (2017), 72–79; https://doi.org/10.1016/j.rcae.2016.11.011Search in Google Scholar
A. N. Mian and G. J. Schwartz, Measurement and estimation of glomerular filtration rate in children, Adv. Chronic Kidney Dis24 (2017) 348–356; https://doi.org/10.1053/j.ackd.2017.09.011Search in Google Scholar
L. Kahl and H. K. Hughes, The Harriet Lane Handbook, 21nd ed., Elsevier, Amsterdam 2018.Search in Google Scholar
ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline 2017; https://www.ema.europa.eu/en/ich-e11r1-step-5-guideline-clinical-investigation-medicinal-products-pediatric-population-scientific; last access date February 20, 2023.Search in Google Scholar
M.-A. Decrocq-Rudler, A. H. X. P. C. Kwong, L. Meunier, J. Fraisse, J. Ursic-Bedoya and S. Khier, Can we predict individual concentrations of tacrolimus after liver transplantation? Application and tweaking of a published population pharmacokinetic model in clinical practice, Ther. Drug Monit.43(4) (2921) 490–498; https://doi.org/10.1097/FTD.0000000000000867Search in Google Scholar
A. Chan Kwong, A. O’Jeanson and S. Khier, Model-informed therapeutic drug monitoring of meropenem in critically ill patients: improvement of the predictive ability of literature models with the PRIOR approach, Eur. J. Drug Metab. Pharmacokinet.46 (2021) 415–426; https://doi.org/10.1007/s13318-021-00681-5Search in Google Scholar
A. Gomes, L. van der Wijk, J. H. Proost, B. Sinha and D. J. Touw, Pharmacokinetic modeling of gentamicin in treatment of infective endocarditis: Model development and validation of existing models, PloS One12(5) (2017) e0177324 (13 pages); https://doi.org/10.1371/journal.pone.0177324Search in Google Scholar
J. H. Hughes, D. M. H. Tong, S. S. Lucas, J. D. Faldasz, S. Goswami and R. J. Keizer, Continuous learning in model-informed precision dosing: a case study in pediatric dosing of vancomycin, Clin. Pharmacol. Ther.109(1) (2021) 233–242; https://doi.org/10.1002/cpt.2088Search in Google Scholar
W. Zhao, F. Kaguelidou, V. Biran, D. Zhang, K. Allegaert, E. V. Capparelli, N. Holford, T. Kimura, Y. L. Lo, J. E. Peris, External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings, Br. J. Clin. Pharmacol.75(4) (2013) 1068–1080; https://doi.org/10.1111/j.1365-2125.2012.04406.xSearch in Google Scholar
C. Schräpel, L. Kovar, D. Selzer, U. Hofmann, F. Tran, W. Reinisch, M. Schwab and T. Lehr, External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease, Pharmaceutics13(9) (2021) Article ID 1368 (21 pages); https://doi.org/10.3390/pharmaceutics13091368Search in Google Scholar
K. R. Knøsgaard, D. J. R. Foster, M. Kreilgaard, E. Sverrisdóttir, R. N. Upton and J. N. van den Anker, Pharmacokinetic models of morphine and its metabolites in neonates: Systematic comparisons of models from the literature, and development of a new meta-model, Eur. J. Pharm. Sci.92 (2016) 117–130; https://doi.org/10.1016/j.ejps.2016.06.026Search in Google Scholar
D. M. Tong, J. H. Hughes and R. J. Keizer, Evaluating and improving neonatal gentamicin pharmacokinetic models using aggregated routine clinical care data, Pharmaceutics14(10) (2022) Article ID 2089 (14 pages); https://doi.org/10.3390/pharmaceutics14102089Search in Google Scholar
A. H.-X. Chan Kwong, E. A. Calvier, D. Fabre, F. Gattacceca and S. Khier, Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine, J. Pharmacokinet. Pharmacodyn.47 (2020) 431–446; https://doi.org/10.1007/s10928-020-09695-zSearch in Google Scholar
A. Duong, C. Simard, D. Williamson and A. Marsot, Model re-estimation: An alternative for poor predictive performance during external evaluations? Example of gentamicin in critically ill patients, Pharmaceutics14(7) (2022) 1426; https://doi.org/10.3390/pharmaceutics14071426Search in Google Scholar
C. C. Llanos-Paez, C. E. Staatz, R. Lawson and S. Hennig, A population pharmacokinetic model of gentamicin in pediatric oncology patients to facilitate personalized dosing, Antimicrob. Agents Chemother.61(8) (2017) e00205-17; https://doi.org/10.1128/AAC.00205-17Search in Google Scholar
S. A. Lopez, H. Mulla, A. Durward and S. M. Tibby, Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness, Pediatr. Crit. Care Med.11(2) (2010) 267–274; https://doi.org/10.1097/PCC.0b013e3181b80693Search in Google Scholar
R. F. W. De Cock, K. Allegaert, J. M. Brussee, C. M. T. Sherwin, H. Mulla, M. de Hoog, J. N. van den Anker, M. Danhof and C. A. J. Knibbe, Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration, Pharm. Res.31 (2014) 2643–2654;, https://doi.org/10.1007/s11095-014-1361-zSearch in Google Scholar
A. Alsultan, M. Abouelkheir, Y. Elsharawy, A. Alkoraishi, R. Osman, M. N. Neely, W. Mansy and S. Algahtani, Optimizing gentamicin dosing in pediatrics using monte carlo simulations, Pediatr. Infect. Dis. J.38(4) (2019) 390–395; https://doi.org/10.1097/INF.0000000000002120Search in Google Scholar
C. C. Llanos-Paez, C. E. Staatz, R. Lawson and S. Hennig, Differences in the pharmacokinetics of gentamicin between oncology and nononcology pediatric patients, Antimicrob. Agents Chemother.64(2) (2020) e01730-19; https://doi.org/10.1128/AAC.01730-19Search in Google Scholar
H. Wang, C. Sherwin, J. V. S. Gobburu and V. Ivaturi, Population pharmacokinetic modeling of gentamicin in pediatrics, J. Clin. Pharmacol.59(12) (2019) 1584–1596; https://doi.org/10.1002/jcph.1479Search in Google Scholar
R. H. Ghoneim, A. K. Thabit, M. O. Lashkar and A. S. Ali, Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation, Ital. J. Pediatr.47 (2021) Article ID 167 (8 pages); https://doi.org/10.1186/s13052-021-01114-4Search in Google Scholar
H. S. Al-Sallami, A. Goulding, A. Grant, R. Taylor, N. Holford and S. B. Duffull, Prediction of fat-free mass in children, Clin. Pharmacokinet.54 (2015) 1169–1178; https://doi.org/10.1007/s40262-015-0277-zSearch in Google Scholar
J. Valles, J. Rello, A. Ochagavía, J. Garnacho and M. A. Alcalá, Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival, Chest123(5) (2003) 1615–1624; https://doi.org/10.1378/chest.123.5.1615Search in Google Scholar
A. Coste, G. Deslandes, L. Jalin, S. Corvec, J. Caillon, D. Boutoille, M. Grégoire and C. Bretonnière, PK/PD targets of amikacin and gentamicin in ICU patients, Méd. Mal. Infect.50(8) (2020) 709–714; https://doi.org/10.1016/j.medmal.2019.12.003Search in Google Scholar
A. A. Marsot, A. Boulamery, B. Bruguerolle and N. Simon, Population pharmacokinetic analysis during the first 2 years of life: an overview, Clin. Pharmacokinet.51 (2012) 787–798; https://doi.org/10.1007/s40262-012-0015-8Search in Google Scholar
F. Ceriotti, J. C. Boyd, G. Klein, J. Henny, J. Queralto, V. Kairisto and M. Panteghini, Reference intervals for serum creatinine concentrations: assessment of available data for global application, Clin. Chem.54(3) (2008) 559–566; https://doi.org/10.1373/clinchem.2007.099648Search in Google Scholar